South Korean biotech SK Biopharmaceuticals has unveiled the Phase III clinical trial results of Xcopri (cenobamate) in Northeast Asian epilepsy patients through a poster presentation at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, USA.
Based on these findings, cenobamate’s partners in Asia plan to proceed with New Drug Application (NDA) submission in their respective countries.
Xcopri is subject to a licensing deal with Japan's Ono Pharmaceutical (TYO: 4528), whereby the latter has rights to develop and commercialize the therapy in Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze